Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.

Cardiovascular adverse events (CVAEs) are recognized complications of chimeric antigen receptor (CAR) T-cell therapies. However, data are lacking regarding subtypes of adverse events that develop in patients with different malignancies, and little is known about the timeframe in which different cardiotoxicities are most likely to occur post-CAR T-cell therapies. In this study, 211 patients, including 138 lymphoma patients and 66 myeloma patients who received CAR T-cell therapies were retrospectively identified.

Converting a Metal-Coordinating Polymer to a Polymerized Ionic Liquid Improves Li Transport.

Solid polymer electrolytes (SPEs) with mechanical strength and reduced flammability may also enable next-generation Li batteries with higher energy densities. However, conventional SPEs have fundamental limitations in terms of Li conductivity. While an imidazole functionalized polymer (PMS-Im) has been previously shown to have ionic conductivity related to the imidazole-Li coordination, herein we demonstrate that quaternization of this polymer to form an analogous imidazolium functionalized polymer (PMS-Im) more efficiently solvates lithium salts and plasticizes the polymer.

Influence of Water Sorption on Ionic Conductivity in Polyether Electrolytes at Low Hydration.

Ion-containing polymers are subject to a wide range of hydration conditions across electrochemical and water treatment applications. Significant work on dry polymer electrolytes for batteries and highly swollen membranes for water purification has informed our understanding of ion transport under extreme conditions. However, knowledge of intermediate conditions (i.

Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1.

PIK-75 (F7) is a potent multikinase inhibitor that targets p110α, DNA-PK, and p38γ. PIK-75 has shown potential as a therapy in preclinical cancer models, but it has not been used in the clinic, at least in part, due to limited solubility. We therefore developed a nanoparticle to encapsulate PIK-75 and enable targeted cellular delivery.